News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


LCT Parkinson’s trial resumes patient recruitment

LCT Parkinson’s trial resumes patient recruitment

23 June 2014 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited today announced that it has received the necessary regulatory approval to resume recruitment of the remaining three patients in the Phase I/IIa clinical trial of NTCELL® in Parkinson’s disease. The trial was paused in December last year while the company completed internal and external audit and regulatory processes.

Dr Ken Taylor, NTCELL Program Director and Acting Chief Executive, is pleased that patient recruitment in the clinical trial of NTCELL for Parkinson’s can resume.

“The completion of the clinical trial is an initial step in progressing NTCELL to commercialisation as the first disease modifying treatment for Parkinson’s disease.”

Existing treatments for Parkinson’s treat the symptoms rather than attempting to regenerate the affected brain cells. Many people with Parkinson’s no longer respond to these treatments.

“LCT is committed to developing and marketing NTCELL for Parkinson’s patients not responding to current therapies. We also intend to further investigate the potential of our patented cell therapy as a treatment for other neurodegenerative disorders,” said Dr Taylor.

Preclinical studies which confirmed NTCELL initiated nerve growth support the development of NTCELL as a potential treatment for other neurological diseases such as Huntington’s, Motor Neuron and Alzheimer’s.

For further information: www.lctglobal.com

About Living Cell Technologies
Living Cell Technologies (LCT) is an Australasian biotechnology company researching and developing cell therapies to treat diseases with high unmet clinical need. LCT’s lead product NTCELL® is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory producing nerve growth factors to promote new central nervous system growth and repair disease induced nerve degeneration.

NTCELL is in Phase I/IIa clinical trial in New Zealand for the treatment of Parkinson’s disease. It has the potential to be used in a number of indications.

LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its research and development, operations and manufacturing facilities based in New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter

ENDS

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Photos: Inside The Christchurch Arts Centre Rebuild

Lady Pippa Blake visited Christchurch Arts Centre chief executive André Lovatt, a 2015 recipient of the Blake Leader Awards. The award celebrated Lovatt’s leadership in New Zealand and hisand dedication to the restoration of the Arts Centre. More>>

Running Them Up The Flagpole: Web Tool Lets Public Determine New Zealand Flag

A School of Design master’s student is challenging the flag selection process by devising a web tool that allows the public to feed their views back in a way, he says, the current government process does not. More>>

ALSO:

Survey: ‘The Arts Make My Life Better’: New Zealanders

New Zealanders are creative people who believe being involved in the arts makes their lives better and their communities stronger. Nine out of ten adult New Zealanders (88%) agree the arts are good for them and eight out of ten (82%) agree that the arts help to improve New Zealand society. More>>

ALSO:

Wellington.Scoop: Reprieve For Te Papa Press

Following its review of the role of Te Papa Press, Te Papa has committed to continue publishing books during the museum’s redevelopment, Chief Executive Rick Ellis announced yesterday. More>>

Law Society: Sir Peter Williams QC, 1934 - 2015

“Sir Peter was an exceptional advocate. He had the ability to put the defence case for his clients with powerful oratory. His passion shone through in everything he did and said.” Mr Moore says Sir Peter’s lifelong commitment to prison reform was instrumental in ensuring prison conditions and the rights of prisoners were brought to public attention. More>>

ALSO:

CTU: Peter Conway – Family Statement

Peter committed his whole working life to improving the lives of working people, both in unions and, more recently, as the Economist and Secretary of the Council of Trade Unions. He was previously Chair of Oxfam New Zealand and was on the Board of NZ Trade and Enterprise. More>>

ALSO:

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news